^
    Back
    Association details:
    Biomarker:SETD3-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Lung Cancer
    Title:

    A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib

    Published date:
    11/30/2022
    Excerpt:
    ...we report a case of advanced lung adenocarcinoma (LUAD) harboring a novel SET domain containing 3 (SETD3)-ALK fusion and sensitive to crizotinib
    DOI:
    https://doi.org/10.1016/j.lungcan.2022.11.020